GRIK3抗体

+ +

•  

   

     Black line: Control Antigen (100 ng);Purple line: Antigen (10ng); Blue line: Antigen (50 ng); Red line:Antigen (100 ng)    

  
  

•  

   

     Immunofluorescence analysis of Hela cells using GRIK3 mouse mAb. Blue: DRAQ5 fluorescent DNA dye. Red: Actin filaments have been labeled with Alexa Fluor- 555 phalloidin.    

  
  

•  

   

     Immunofluorescence analysis of Hela cells using GRIK3 mouse mAb (green). Blue: DRAQ5 fluorescent DNA dye. Red: Actin filaments have been labeled with Alexa Fluor- 555 phalloidin. Secondary antibody from Fisher (Cat#: 35503)    

  
  

The glutamate receptor ionotropic kainate 3 (GRIK3), also known as GluK3. is a subunit of kainate receptors, a subclass of ionotropic glutamate receptors critical for fast excitatory neurotransmission in the central nervous system. Encoded by the *GRIK3* gene, this protein forms ligand-gated ion channels that mediate synaptic plasticity, neuronal development, and excitatory signaling. GRIK3-containing receptors are primarily expressed in the brain, particularly in the hippocampus, cerebellum, and cortex, where they modulate presynaptic neurotransmitter release and postsynaptic depolarization.

Antibodies targeting GRIK3 are essential tools for studying its expression, localization, and function in neurological processes. They are widely used in techniques like Western blotting, immunohistochemistry, and immunofluorescence to investigate protein levels in tissue samples or cell cultures. Research involving GRIK3 antibodies has helped elucidate its role in neuropsychiatric and neurodegenerative disorders, including schizophrenia, epilepsy, and autism spectrum disorders. For instance, altered GRIK3 expression has been linked to synaptic dysfunction, suggesting its potential as a therapeutic target or biomarker.

These antibodies also aid in exploring the structural diversity of kainate receptors, as GRIK3 can combine with other subunits (GluK1-2. GluK4-5) to form heteromeric receptors with distinct pharmacological and electrophysiological properties. Validation of GRIK3 antibodies—through knockout controls or peptide blocking—is crucial to ensure specificity, given the high homology among glutamate receptor subunits. Ongoing research continues to uncover its regulatory mechanisms and pathophysiological relevance in brain disorders.